At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 71 enrolled
Drug / intervention
Pegylated-Interferon-lambda +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3 Study Evaluating the Safety and Efficacy of Lambda/Ribavirin/Daclatasvir in Subjects With Chronic HCV Infection and Underlying Hemophilia Who Are Treatment Naïve or Are Prior Relapsers to Peginterferon Alfa-2a/Ribavirin
In Brief
A Phase 3 clinical trial evaluating Pegylated-Interferon-lambda, Ribavirin, and 1 other intervention for Hepatitis C Virus. Completed, enrolled 71 participants across 32 sites in 8 countries.
Detailed Summary
The primary objective for this study is to evaluate the proportion of subjects who achieve SVR12 (HCV RNA \< LLOQ (target not detected) at post-treatment follow-up Week 12 in subjects with Genotype(GT)-1b, -4 and GT-2, -3
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis C Virus
CountriesAustralia, France, Italy, Netherlands, Romania, Russia, Spain, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedDec 2012
Enrollment StartMar 2013
Primary CompletionJan 2015
TodayJul 2026
First PostedDec 5, 2012
Enrollment StartMar 31, 2013
Primary CompletionJan 31, 2015
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 13.6 years ago
Interventions
Pegylated-Interferon-lambdabiological
Ribavirindrug
Daclatasvirdrug